To update and integrate the recommendations for ankylosing spondylitis and the recommendations
for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA…

Objectives To update the Assessment of SpondyloArthritis international Society (ASAS)-EULAR
recommendations for the management of axial spondyloarthritis (axSpA). Methods …

Objective Patients with rheumatoid arthritis (RA) in whom the response to anti–tumor
necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as …

Infection with severe acute respiratory syndrome coronavirus 2 associates with diverse
symptoms, which can persist for months. While antiviral antibodies are protective, those targeting …

Objectives To analyse the impact of tumour necrosis factor inhibitors (TNFis) on spinal
radiographic progression in ankylosing spondylitis (AS). Methods Patients with AS in the Swiss …

Objective Tumor necrosis factor (TNF) inhibitors have revolutionized the treatment of severe
rheumatoid arthritis (RA), yet drug discontinuation is common. The aim of this study was to …

Polyclonal hypergammaglobulinemia is a characteristic of chronic inflammatory conditions,
including persisting viral infections and autoimmune diseases. Here we have studied …

Objective To evaluate the baseline characteristics of patients with radiographic axial
spondyloarthritis (SpA; ankylosing spondylitis [AS]) and patients with nonradiographic axial SpA, to …

Objective The first 3 months after symptom onset represent an important therapeutic window
for rheumatoid arthritis (RA). This study investigates the extent and causes of delay in …

Objective Limited data have been published on tolerance to and efficacy of classic or
biologic disease‐modifying antirheumatic drugs in elderly patients with rheumatoid arthritis (RA). …